Fertility and Gonadal Function after First-Line Treatment with Nivolumab-AVD in Hodgkin Lymphoma Patients: An Analysis from the Phase II GHSG Nivahl Trial

被引：0
|
作者：
Broeckelmann, Paul J. [1 ]
Buehnen, Ina [1 ]
Herhaus, Peter [2 ]
Meissner, Julia [3 ]
Trautmann-Grill, Karolin [4 ]
Mueller, Horst [1 ]
Fuchs, Michael [1 ]
von Tresckow, Bastian [5 ]
Borchmann, Peter [1 ]
Engert, Andreas [1 ]
Behringer, Karolin [1 ]
机构：
[1] Univ Hosp Cologne, Dept Internal Med, German Hodgkin Study Grp GHSG, Cologne, Germany
[2] Tech Univ Munich, Sch Med, Clin & Policlin Internal Med 3, Klinikum Rechts Isar, Munich, Germany
[3] Univ Hosp Heidelberg, Med 5, Heidelberg, Germany
[4] Univ Hosp Carl Gustav Carus, Med Clin 1, Dresden, Germany
[5] West German Canc Ctr Essen, Dept Hematol & Stem Cell Transplantat, Essen, Germany
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-189250
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Quality of Life with Nivolumab and AVD First-Line Treatment in Hodgkin Lymphoma: Patient-Reported Outcomes from the Phase II GHSG Nivahl Trial
    Broeckelmann, Paul J.
    Buehnen, Ina
    Herhaus, Peter
    Meissner, Julia
    Trautmann-Grill, Karolin
    Mueller, Horst
    Fuchs, Michael
    von Tresckow, Bastian
    Borchmann, Peter
    Engert, Andreas
    Behringer, Karolin
    BLOOD, 2023, 142
  • [2] Quality of Life with Nivolumab and AVD First-Line Treatment in Hodgkin Lymphoma: Patient-Reported Outcomes from the Phase II GHSG NIVAHL Trial
    Broeckelmann, Paul J.
    Buehnen, Ina
    Herhaus, Peter
    Meissner, Julia
    Trautmann, Karolin
    Mueller, Horst
    Fuchs, Michael
    von Tresckow, Bastian
    Borchmann, Peter
    Engert, Andreas
    Behringer, Karolin
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 115 - 115
  • [3] Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Follow-up Analysis of the Randomized GHSG Phase II Nivahl Trial
    Broeckelmann, Paul J.
    Buehnen, Ina
    Meissner, Julia
    Trautmann-Grill, Karolin
    Herhaus, Peter
    Halbsguth, Teresa, V
    Schaub, Valdete
    Kerkhoff, Andrea
    Mathas, Stephan
    Bormann, Matthias
    Dickhut, Andreas
    Kaul, Helen
    Fuchs, Michael
    Kobe, Carsten
    Baues, Christian
    Borchmann, Peter
    Engert, Andreas
    von Tresckow, Bastian
    BLOOD, 2022, 140 : 1753 - 1755
  • [4] Efficacy and Safety of Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Extended Follow-up from the GHSG Phase II Nivahl Trial
    Brockelmann, Paul J.
    Goergen, Helen
    Keller, Ulrich
    Meissner, Julia
    Trautmann, Karolin
    Halbsguth, Teresa V.
    Sasse, Stephanie
    Sokler, Martin
    Kerkhoff, Andrea
    Mathas, Stephan
    Huttmann, Andreas
    Bormann, Matthias
    Zimmermann, Andreas
    Fuchs, Michael
    von Tresckow, Bastian
    Baues, Christian
    Rosenwald, Andreas
    Klapper, Wolfram
    Kobe, Carsten
    Borchmann, Peter
    Engert, Andreas
    BLOOD, 2020, 136
  • [5] Fertility and Gonadal Function After Treatment of Early Unfavorable Hodgkin Lymphoma (HL): An Analysis of the German Hodgkin Study Group (GHSG)
    Behringer, Karolin
    Thielen, Indra
    Mueller, Horst
    Goergen, Helen
    Eibl, Angelika
    Rosenbrock, Johannes
    Halbsguth, Teresa
    Reiners, Katrin S.
    Diehl, Volker
    Engert, Andreas
    Borchmann, Peter
    BLOOD, 2011, 118 (21) : 199 - 199
  • [6] Phase II Clinical Trial of Camrelizumab Combined with AVD (Epirubicin, Vincristine and Dacarbazine) in the First-Line Treatment for Patients with Advanced Classical Hodgkin's Lymphoma
    Zhao, Shuang
    Liu, Yanyan
    Yao, Zhihua
    Yan, Zheng
    Yao, Shuna
    Chu, Junfeng
    Wang, Haiying
    Zhang, Jiuyang
    Zhang, Peipei
    Zhou, Wenping
    BLOOD, 2022, 140 : 6579 - 6580
  • [7] Early Response to First-Line Anti-PD-1 Treatment in Hodgkin Lymphoma: A PET-Based Analysis from the Prospective, Randomized Phase II NIVAHL Trial
    Voltin, Conrad-Amadeus
    Mettler, Jasmin
    van Heek, Lutz
    Goergen, Helen
    Mueller, Horst
    Baues, Christian
    Keller, Ulrich
    Meissner, Julia
    Trautmann-Grill, Karolin
    Kerkhoff, Andrea
    Fuchs, Michael
    Sasse, Stephanie
    von Tresckow, Bastian
    Dietlein, Markus
    Borchmann, Peter
    Engert, Andreas
    Kobe, Carsten
    Broeckelmann, Paul J.
    CLINICAL CANCER RESEARCH, 2021, 27 (02) : 402 - 407
  • [8] Metabolic Tumor Volume for Early Response Assessment in Early-Stage Unfavorable Hodgkin Lymphoma Treated with Nivolumab in the GHSG Nivahl Phase II Trial
    Voltin, Conrad-Amadeus
    Mettler, Jasmin
    Mueller, Horst
    Fuchs, Michael
    Baues, Christian
    Dietlein, Markus
    Engert, Andreas
    Borchmann, Peter
    Kobe, Carsten
    Brockelmann, Paul J.
    BLOOD, 2019, 134
  • [9] Clinical outcomes of relapsed Hodgkin lymphoma patients after contemporary first-line treatment: Results from the German Hodgkin Study Group (GHSG)
    Brockelmann, P.
    Muller, H.
    Gillessen, S.
    Yang, X.
    Koppel, L.
    Pilz, V
    Marinello, P.
    Kaskel, P.
    Raut, M.
    Fuchs, M.
    Borchmann, P.
    Engert, A.
    von Tresckow, B.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 37 - 37
  • [10] Nivolumab First-Line Therapy for Elderly, Frail Hodgkin Lymphoma Patients: Niviniho, a Lysa Phase II Study
    Lazarovici, Julien
    Amorim, Sandy
    Bouabdallah, Krimo
    Guidez, Stephanie
    Molina, Lysiane
    Morschhauser, Franck
    Gac, Anne-Claire
    Gastinne, Thomas
    Laribi, Kamel
    Launay, Vincent
    Slama, Bohrane
    Belmecheri, Nawel
    Casasnovas, Rene-Olivier
    Corby, Anne
    Durot, Eric
    Feugier, Pierre
    Nicolas-Virelizier, Emmanuelle
    Sibon, David
    Berriolo-Riedinger, Alina
    Edeline, Veronique
    Vander Borght, Thierry
    Damotte, Diane
    Traverse-Glehen, Alexandra
    Andre, Marc
    Ribrag, Vincent
    BLOOD, 2021, 138
12345